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Abstract
Introduction Aggrecanase cleavage at the 392Glu-393Ala bond
in the interglobular domain (IGD) of aggrecan, releasing N-
terminal 393ARGS fragments, is an early key event in arthritis and
joint injuries. Here, we use a quantitative immunoassay of
aggrecan ARGS neoepitope fragments in human synovial fluid
to determine if this cleavage-site specific method better
identifies joint pathology than previously available less specific
aggrecan assays.
Methods Synovial fluid (SF) from 26 people with healthy knees
(reference) and 269 patients were analyzed in a cross-sectional
study. Patient groups were acute inflammatory arthritis, acute
knee injury, chronic knee injury and knee osteoarthritis (OA).
Aggrecan ARGS fragments were assayed by ELISA using the
monoclonal antibody OA-1. Total aggrecan content was
analyzed by an ELISA using the monoclonal antibody 1-F21, and
sulfated glycosaminoglycan by Alcian blue precipitation.
Results Aggrecan ARGS fragment concentrations in all groups
differed from the reference group (P  < 0.001). The acute
inflammatory arthritis group had the highest median level, 177-
fold greater than that of the reference group. Median levels (in
pmol ARGS/ml SF) were: reference 0.5, acute inflammatory
arthritis 88.5, acute knee injury 53.9, chronic knee injury 0.5 and
OA 4.6. In contrast, aggrecan and sulfated glycosaminoglycan
concentrations varied much less between groups, and only
acute inflammatory arthritis and acute knee injury were found to
have a two-fold increase in median levels compared to the
reference.
Conclusions Levels of aggrecan ARGS fragments in human
synovial fluid are increased in human arthritis, OA and after knee
injury, likely reflecting an enhanced cleavage at the 392Glu-
393Ala bond in the IGD by aggrecanase. An assay that
specifically quantified these fragments better distinguished
samples from joints with pathology than assays monitoring
aggrecan or glycosaminoglycan concentrations. The newly
developed ARGS fragment assay can be used to monitor
aggrecanase activity in human joint disease and experimental
models.
Introduction
Proteolysis of aggrecan is an early and critical feature of carti-
lage degradation in arthritis and after knee injury, and is meas-
urable as an elevation of aggrecan release from the cartilage
into the synovial fluid (SF) [1-4]. Although proteases, such as
matrix metalloproteases (MMPs), cathepsins and calpains, are
involved [5], aggrecanase plays a major role in aggrecan deg-
radation in murine [6,7] and human [4,8-15] joint disease.
There are five known aggrecanase cleavage sites in aggrecan
[16]. The most severe aggrecanase cleavage in terms of
destructive loss of sulfated glycosaminoglycan (sGAG) from
the tissue, is at the 392Glu-393Ala bond in the interglobular
AA: acute inflammatory arthritis; ACL: anterior cruciate ligament; ADAMTS: a disintegrin and metalloproteinase with thrombospondin motifs; AEBSF: 
4-(2-aminoethyl)-benzenesulfonyl fluoride; AI: acute knee injury; BSA: bovine serum albumin; CI: chronic knee injury; CV: coefficient of variation; 
EACA: 6-aminohexonic acid; EDTA: ethylenediaminetetra acetic acid; ELISA: enzyme-linked immunosorbent assay; H2O2: hydrogen peroxidase; IGD: 
interglobular domain; KS: keratan sulfate; mAb: monoclonal antibody; MEN: meniscal injury; MES: 2-(N-morpholino) ethanesulfonic acid; MMP: matrix 
metalloproteases; NEM: N-ethylmaleimide; OA: osteoarthritis; PBST: phosphate buffered saline with TWEEN; PMSF: phenylmethylsulfonyl fluoride; 
PVDF: polyvinylidene difluoride; REF: healthy knee reference; SF: synovial fluid; sGAG: sulfated glycosaminoglycan; TMB: tetramethylbenzidine.Arthritis Research & Therapy    Vol 11 No 3    Larsson et al.
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(IGD) domain of aggrecan, releasing N-terminal 393ARGS
neoepitope fragments.
ARGS neoepitope aggrecan fragments released into the SF,
as detected by western blot or amino acid sequencing, have
been associated with joint diseases [4,8,9,17,18] and have
also been detected as a result of normal turnover [4,17].
When quantified by a western blot method, the proportion of
aggrecan in SF having the neoepitope ARGS was elevated in
arthritis and joint injury compared with individuals with healthy
knees [4]. Fragments carrying the same neoepitope were also
found in serum from patients with rheumatoid arthritis, but not
in healthy controls [15].
Results from several ELISAs have been presented that meas-
ure levels of aggrecan neoepitopes in medium from human
cartilage explants [10,11,13,19]. By measuring neoepitope
concentrations, aggrecanase cleavage at the 392Glu-393Ala
bond has been confirmed as a major contributor to aggrecan
loss from cartilage stimulated by cytokines [10,11,13-15].
However, with the exception of small-scale quantitative west-
ern blots [4], only assays of non-specific aggrecan fragments
[1,20], of newly synthesized aggrecan bearing the 846
epitope [21] or of sGAG [22] have been reported in studies of
human SF.
In this cross-sectional study, comparing people with healthy
knees with those with acute inflammatory arthritis, acute knee
injury, chronic knee injury, or knee osteoarthritis (OA), we
quantified the SF levels of the aggrecan ARGS neoepitope
with a modified sandwich ELISA [19], and compared it with
aggrecan assays not specific for this neoepitope. We hypoth-
esized that ARGS neoepitope concentrations in SF would dif-
fer between these groups and be a more sensitive measure of
joint disease than previously used aggrecan or sGAG assays.
Materials and methods
Amino acid numbering
All amino acid numbering of aggrecan is herein based on full-
length human aggrecan, accession number [Swiss-
Prot:P16112], starting with the N-terminal 1MTTL-amino acid
sequence.
Materials
Alcian blue 8GS (C.I. 742240) was from Chroma-Gesells-
chaft (Köningen, Germany). 4-(2-aminoethyl)-benzenesulfonyl
fluoride (AEBSF), 6-aminohexonic acid (EACA), benzamidine-
HCl, BSA, chondroitin sulfate type C from shark cartilage (no.
C4384), ethylenediaminetetra acetic acid (EDTA), N-ethyl-
maleimide (NEM), 2-(N-morpholino) ethanesulfonic acid
(MES), phenylmethylsulfonyl fluoride (PMSF), and phosphate
buffered saline with TWEEN (PBST) buffer (0.01 M sodium
phosphate, 0.138 M sodium chloride, 0.0027 M potassium
chloride, 0.05% TWEEN 20; pH 7.4) were from Sigma (St.
Louis, MO, USA). Cesium chloride and guanidinium hydro-
chloride were from Merck (Darmstadt, Germany). Molecular
weight markers 10 to 250 kDa (no. 161-0373) were from Bio-
Rad (Hercules, CA, USA). Human recombinant ADAMTS-4 (a
disintegrin and metalloproteinase with thrombospondin motifs,
aggrecanase-1) was from GlaxoSmithKline (Collegeville, PA,
USA) [23]. ECL Plus detection was from Amersham Bio-
sciences (Buckinghamshire, UK). Polyvinylidene difluoride
(PVDF) membranes, Tris-acetate mini gels (3 to 8%), LDS
sample buffer, Tris-acetate SDS running buffer and transfer
buffer were from Invitrogen (Carlsbad, CA, USA). Non-fat dry
milk by Semper (Sundbyberg, Sweden) was from the local
supermarket.
Quick-Seal centrifuge tubes (2 ml no. 344625, 12.5 ml no.
342413), tube sealer (no. 342428), tube slicer (no. 303811)
were from Beckman Coulter (Palo Alto, CA, USA). The mono-
clonal antibody (MAb) OA-1, with or without biotinylation, rec-
ognizing the neoepitope sequence ARGSVIL (representing
the N-terminus of human aggrecan cleaved between 392Glu
and 393Ala in the interglobular domain) was kindly provided by
Michael Pratta (GlaxoSmithKline, Collegeville, PA, USA) [19].
Tetramethylbenzidine (TMB)-hydrogen peroxidase (H2O2)
solution (no. 50-76-00) and peroxidase labeled streptavidin
(no. 14-30-00) were from KPL (Gaithersburg, MD, USA).
Hyaluronidase from Streptomyces hyalurolyticus (EC 4.2.2.1),
chondroitinase ABC protease free (EC 4.2.2.4), keratanase
(EC 3.2.1.103) and keratanase II (from Bacilus species Ks 36)
were from Seikagaku (Tokyo, Japan). Keratan sulfate (KS) cap-
ture 96-well plates (no. 42.146.08) were from Biosource Inter-
national (Camiro, CA, USA).
Subjects and samples
Knee SF from 26 knee healthy volunteers and 269 patients
were obtained from a cross-sectional convenience cohort,
where each individual, after informed consent, provided a sam-
ple at one time point only. Diagnosis was made by arthros-
copy, radiography, assessment of SF and clinical examination
[1]. Samples were centrifuged at 3000 g and aliquots of the
supernatant were stored at -80°C. All patient-related proce-
dures were approved by the ethics review committee of the
Medical Faculty of Lund University.
Diagnostic groups were healthy knee references (REF), acute
inflammatory knee arthritis (AA), knee OA, and injured knee
(anterior cruciate ligament rupture and/or meniscus tear)
grouped as acute knee injury (AI; 0 to 12 weeks after injury) or
chronic knee injury (CI; > 12 weeks after injury; Table 1). Joint
changes, assessed by arthroscopy and radiography, were
scored ranging from 1 to 10, where 1 represents a normal joint
by arthroscopy and radiography; 2 to 5 represents an increas-
ing extent and severity of fibrillation and clefts in the joint car-
tilage by arthroscopy in joints appearing normal on
radiographs; and 6 to 10 represents increasing degrees of
radiographic joint space narrowing consistent with OA [24].Available online http://arthritis-research.com/content/11/3/R92
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Thirty-one samples lacked arthroscopic and/or radiographic
data needed for assessment of OA score.
To study injury-dependent aggrecan fragment release at differ-
ent times after injury, these samples were grouped as meniscal
injury alone (MEN) or cruciate ligament rupture with or without
an associated meniscus injury (ACL), stratified by time after
injury (0 to 4, 4 to 12, 12 to 26, 26 to 52, or > 52 weeks).
Patient samples were selected from a biobank by one of the
authors (LSL) on the basis of clinical diagnosis, without refer-
ence to any previously available assay data.
Cartilage aggrecan digest as ARGS standard
From the pool of human knee OA cartilage (10 patients) pro-
teoglycans were extracted with guanidinium hydrochloride (4
M) in the presence of proteinase inhibitors (10 mM EDTA, 100
mM EACA, 10 mM NEM, 5 mM benzamidine-HCl and 5 mM
PMSF) and aggrecan was then isolated by associative-disso-
ciative cesium chloride density gradient centrifugation in the
presence of the proteinase inhibitors [25]. Fraction A1D1 was
collected and dialyzed against Millipore-water prior to freeze
drying [18]. As described, this fraction contains only large
aggrecan fragments, containing the IGD, without G1-IPEN
and G1-TEGE fragments [18]. Human aggrecan monomers
were quantified based on dry weight assuming a molecular
weight of 1.5 × 106 g/mol.
Full-length human recombinant ADAMTS-4 was cloned,
expressed, and purified at GlaxoSmithKline (Collegeville, PA,
USA) [23]. ADAMTS-4 (3.1 nM) was incubated with the A1D1
fraction of human aggrecan (346 nM) for 30 hours at 37°C in
50 mM Tris-HCl, 100 mM sodium chloride (NaCl), 10 mM cal-
cium chloride (CaCl2), pH 7.5, achieving complete conversion
of the G1-containing starting material to G1-TEGE fragments
and the corresponding ARGS fragments. The digest was
quenched with 25 mM EDTA and monitored for complete
digestion by G1, TEGE, and ARGS western blots (data not
shown). The digest was used as an ARGS standard in the
aggrecan ARGS ELISA.
Aggrecan ARGS ELISA
Quantification in SF of aggrecan fragments with the N-terminal
393ARGS was by a sandwich ELISA using an anti-KS antibody
as capture and the monoclonal neoepitope antibody OA-1 for
detection of specific fragments [19]. After modification for use
in SF, the assay was conducted as follows:
Sample treatment
ARGS standard (ADAMTS-4 digested cartilage A1D1 aggre-
can) was treated with chondroitinase ABC as described [18].
SF samples were digested with hyaluronidase (0.01 turbidity
reducing unit/μl SF for three hours at 60°C in 50 mM sodium
acetate, 10 mM EDTA, 0.25 mM AEBSF, pH 6), treated with
chondroitinase ABC (0.8 mU/μl SF for 30 minutes at 37°C in
50 mM Tris-acetate, 75 mM sodium acetate, 15 mM EDTA,
0.125 mM AEBSF, pH 7.6), boiled in a water bath for five min-
utes, and spun (12,500 g, five minutes) collecting the super-
natant.
ELISA
Duplicates of 300 μl of ARGS standards (ADAMTS-4
digested cartilage A1D1 aggrecan; 0.02 to 1 nM ARGS) or
supernatant of boiled and spun SF samples (final SF dilution
1:50 to 1:6400) were incubated in the presence of 1% w/v
BSA, 20 mM MES, 150 mM NaCl, pH 5.3 on KS capture
plates coated with an anti-KS antibody (Biosource Interna-
tional, Camiro, CA, USA) over night at 4°C on a plate shaker.
Following washes (6 × 400 μl PBST), plates were incubated
with biotinylated MAb OA-1 (150 μl/well, 1.5 μg/ml in PBST
with 0.1% w/v non-fat dry milk) for two hours at 37°C on a
plate shaker. Plates were washed (as above) and incubated
Table 1
Characteristics of the study patients and reference group
OA score
Study group Subject number Male, % Age, years Time of sampling, weeks after injury or onset no.
REF 26 62 27 (17 to 89) - 1 (1 to 1) 16
AA 48 60 66 (30 to 92) 0.4 (0 to 510) 7 (3 to 9) 31
AI 69 81 27 (16 to 59) 1.4 (0 to 11.9) 1 (1 to 5) 67
CI 123 77 40 (16 to 70) 61 (12.7 to 1926) 2 (1 to 8) 121
OA 29 66 61 (25 to 92) 125 (0 to 772) 7 (2 to 9) 29
Age, time of sampling and OA score in median values (range).
REF = healthy knee reference; AA = acute inflammatory arthritis (46 acute pyrophosphate arthritis/pseudogout, one rheumatoid arthritis and one 
acute reactive arthritis/Yersinia); AI = acute knee injury (47 anterior cruciate ligament ruptures and one posterior, with or without meniscus tear 
and meniscus tear alone, 0 to 12 weeks after injury); CI = chronic knee injury (120 anterior cruciate ligament ruptures and three posterior, with or 
without meniscus tear and meniscus tear alone, > 12 weeks after injury); OA = knee osteoarthritis. The OA score ranges from 1 to 10 where 1 
represents a normal joint; see Materials and Methods for a detailed description.Arthritis Research & Therapy    Vol 11 No 3    Larsson et al.
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with horseradish peroxidase-conjugated streptavidin (150 μl/
well, 1 μg/ml in PBST) for one hour at room temperature on a
plate shaker. Following a wash, a five-minute incubation of
TMB-H2O2 solution (150 μl/well) and acidification with 1 M
phosphoric acid (150 μl/well), absorbance at 450 nm was
measured spectrophotometrically using a Multiscan Multisoft
plate reader (Labsystems, Helsinki, Finland) and the software
Ascent 2.4.2 (Thermo Electron, Waltham, WA, USA).
Spiking
SF from individuals with ARGS concentrations suited for anal-
ysis diluted at 1:50, 1:400, 1:800, and 1:1600 were spiked
with equimolar concentrations of ARGS standard (ADAMTS-
4-digested cartilage A1D1 aggrecan) and analyzed in the
ARGS ELISA.
ARGS neoepitope assays were performed with no knowledge
of clinical diagnosis or previous assay data.
Aggrecan and sGAG quantification in synovial fluid
Aggrecan content was analyzed by a slightly modified compe-
tition ELISA using the mAb 1-F21 recognizing a protein
sequence within or close to the KS domain [20,26]. The 1-F21
ELISA differed from the original [20] as follows: concentration
of chondroitinase-digested A1D1 was 1.25 μg/ml when coat-
ing; all washes were 3 × 200 μl; plates were blocked after
coating (1% BSA, 200 μl/well, 30 minutes at room tempera-
ture); the primary antibody 1-F21 was diluted to 1:10,000; the
secondary antibody (Dakopat nr. P447) was diluted to
1:2000.
Concentration of sGAG was measured by Alcian blue precip-
itation modified from Björnsson [22]. Samples and chondroitin
sulfate standards (25 μl) were precipitated for two hours at
4°C with 0.04% w/v Alcian blue, 0.72 M guanidinium hydro-
chloride, 0.25% w/v Triton X-100, and 0.1% v/v H2SO4 (0.45
ml). The precipitates were collected after centrifugation
(16,000 g, 15 minutes, 4°C), then dissolved in 4 M guanidin-
ium hydrochloride, 33% v/v 1-propanol (0.25 ml), and trans-
ferred to 96-well micro-titer plates prior to absorbance
measurement at 600 nm.
These data were available from previous studies using these
samples [26-28].
For molar comparison of ARGS fragments and aggrecan, con-
version from microgram sGAG/ml to pmol aggrecan/ml was
made assuming an average aggrecan molecular weight of 1.5
× 106 g/mol and assuming that 75% of this weight was sGAG
[4].
Western blot
Aggrecan fragments captured in the ARGS ELISA by the anti-
KS antibodies were analyzed by western blot. Following a
completed ARGS ELISA, plates were washed with PBST and
incubated with 4 M guanidinium hydrochloride (150 μl/well)
for 30 minutes at room temperature on a plate shaker. To
obtain enough material for western blot analysis, the well con-
tents of standard wells (74 wells) and wells of SF from 152
patients (152 wells) were pooled separately and dialyzed in
10,000 kDa cut-off dialysis cassettes (Slide-A-Lyzer, Pierce,
Rockford, IL, USA) against Millipore water containing protease
inhibitors [18]. Samples were freeze dried, dissolved in degly-
cosylation buffer and digested by chondroitinase, keratanase
and keratanase II [18]. Samples were precipitated in ice-cold
acetone, and pellets were dissolved in two times concentrated
sample buffer.
ADAMTS-4 digested aggrecan (used in the ELISA as stand-
ard) and a D1 fraction of pooled SF from 40 OA patients were
chondroitinase, keratanase and keratanase II digested [18].
All samples were run on a 3 to 8% Tris-acetate SDS-PAGE
gel, transferred to a PVDF membrane and ARGS fragments
were visualized using the MAb OA-1 [18].
Western blot quantification
Quantification of ARGS fragment in SF by western blot was
performed as described [4] using the same mAb for detection
(OA-1) and the same standard as in the ARGS ELISA.
Statistical analysis
For some patients the available volume of SF was not large
enough to perform all assays, which explains the variation in
numbers between assays. Of the 295 subjects, 113 had
ARGS fragment values below the level of detection (i.e. < 1
pmol ARGS/ml SF). Each was assigned a value of 0.5 pmol
ARGS/ml, or half the lower limit of detection. To assess differ-
ences among the study groups, either a two-tailed Mann-Whit-
ney U rank sum test with Bonferroni correction was used after
Kruskal-Wallis testing, or a Chi-squared test, as appropriate.
For correlation analysis Spearman's rank order correlation (rS)
was used. P values below 0.05 were considered significant
unless otherwise noted. Statistical calculations were per-
formed using Statistical Package for the Social Sciences
(SPSS, Chicago, IL, USA) for Windows version 15.0.
Results
Technical performance of the ARGS ELISA
SF samples needed to be diluted 1:50 or more for a linear
recovery at different dilutions; at dilutions below 1:50 the sig-
nal was reduced due to unknown matrix effects (results not
shown). With a linear measuring range for the standards of
0.02 to 1 pmol ARGS/ml, and a minimal dilution of SF of 1:50,
the lower limit of detection was then recalculated to undiluted
SF 1 pmol ARGS/ml SF. Intra assay coefficient of variation
(CV) was 6% (n = 10), the inter assay CV for the two groups
of KS capture plates used were 12% (n = 5) and 16% (n =
23), respectively, and the total inter assay CV for the control
SF sample included on all plates was 20% (n = 28; Table 2).Available online http://arthritis-research.com/content/11/3/R92
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The mean spiking recovery at dilutions 1:50 to 1:1600 was
99% (range 75 to 121%; Table 2).
Anti-ARGS western blot analysis of aggrecan fragments cap-
tured by the ELISA plates, showed that the ARGS fragments
present in the standard were also captured by the anti-KS
plates (Figure 1). The SF ARGS fragments captured by the
plates showed the same fragment pattern as those detected
in an SF D1 control sample and in the two standard samples.
Aggrecan, sGAG, and ARGS fragment concentrations in 
synovial fluid
The concentrations of aggrecan measured as 1-F21 reactivity,
sGAG, and aggrecan fragments bearing the ARGS
neoepitope are summarized in Table 3. As shown [26], there
was a strong correlation between aggrecan fragment concen-
tration measured by the 1-F21 ELISA and the concentration of
sGAG (rS = 0.82, data not shown). The ARGS concentration
showed a more moderate correlation with the concentrations
of sGAG (rS = 0.69; Figure 2a) and aggrecan (rS = 0.66; Fig-
ure 2b).
To validate the identity of the fragments responsible for the
signal below the detection limit of the ARGS ELISA, 32 sam-
ples, of which 10 were below ELISA detection, were analyzed
by western blot quantification [4], using the same mAb for
detection, and compared with aggrecan fragment content as
measured by sGAG. The molar proportion of aggrecan frag-
ments bearing the ARGS neoepitope (i.e. ARGS/aggrecan)
as measured by western blot was calculated. In the 10 sam-
ples below the detection limit of the ELISA, the median propor-
tion of ARGS-bearing fragments out of aggrecan was 1.8%
(range 1.2 to 6.4%) and in the samples above the detection
limit, the median proportion was 23.8% (2.6 to 59.2%). Con-
version from μg sGAG/ml to pmol aggrecan/ml is described in
Material and Methods.
Aggrecan ARGS fragments in diagnostic groups
Concentrations of aggrecan fragments carrying the
neoepitope ARGS were elevated in all groups compared with
the healthy knee reference group (Figure 3a). The median lev-
els (in pmol ARGS/ml SF) were: REF 0.5 (range 0.5 to 3.3),
AA 88.5 (0.5 to 961), AI 53.9 (0.5 to 946), CI 0.5 (0.5 to 266),
and OA 4.6 (0.5 to 318). Similarly, all patient groups differed
from the reference (P < 0.001) regarding the proportion of
samples in each diagnostic group with ARGS concentration
above the lower limit of detection (1 pmol ARGS/ml) as tested
Table 2
Technical performance of the KS capture OA-1 ARGS ELISA
Linear measuring range of standard 0.02 to 1 pmol/ml
Minimal dilution of SF 1:50
Minimal detectable concentration in neat SF 1 pmol/ml SF
Intra assay CV (n = 10) 6.1%
*Inter assay, intra lot CV (n = 5, 1st lot) 12.2%
*Inter assay, intra lot CV (n = 23, 2nd lot) 15.6%
Inter assay, inter lot CV (n = 28) 19.7%
Dilution of SF 1:50 1:400 1:800 1:1600
Spiking recovery (mean; range) 116%;
109 to 121%
93%;
75 to 104%
81%;
75 to 88%
104%;
98 to 113%
* Between assay variation in lot numbers (1st, #5L21/1; 2nd, #7F25/1) of the KS capture plates from Biosource.
CV = coefficient of variation; KS = keratan sulfate; SF = synovial fluid.
Figure 1
Anti-ARGS western blot of ELISA-captured material Anti-ARGS western blot of ELISA-captured material. Aggrecan frag-
ments captured by the anti-keratan sulfate (KS)-coated plates were 
extracted after a completed ELISA and analyzed by western blot. Sev-
enty-four wells of captured ARGS standards (STD) and 152 wells of 
SF from 152 patients were used. The samples were chondroitinase, 
keratanase, and keratanase II digested, separated on a SDS-PAGE gel, 
transferred to a polyvinylidene difluoride (PVDF) membrane and probed 
with the ARGS antibody OA-1. For comparison, the STD (0.5 μg sul-
fated glycosaminoglycan (sGAG)/well) and an SF D1 sample pooled 
from 40 osteoarthritis (OA) patients (0.75 μg sGAG/well) were used 
as controls. The size (kDa) and position of the molecular weight mark-
ers are indicated.Arthritis Research & Therapy    Vol 11 No 3    Larsson et al.
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by Chi-squared tests. The percentages of detectable samples
were 96% (AA), 87% (AI), 46% (CI), and 62% (OA) com-
pared with 7.7% in REF. The sensitivity of ARGS fragment
concentration as a marker for joint disease was 67% with a
specificity of 92% (Table 4). We found no significant influence
of age or sex on the SF levels of ARGS fragments (data not
shown).
sGAG and aggrecan in diagnostic groups
Median concentrations of sGAG were elevated only in the AA
(P = 0.004) and AI groups (P < 0.001) compared with the
REF group (Figure 3b). Similarly, concentrations of aggrecan
measured by the 1-F21 ELISA were different from REF only in
AA (P = 0.002) and AI (P = 0.026; Figure 3c). The sensitivities
of sGAG and aggrecan fragment concentrations as markers
for disease were 40% and 32% with specificities of 92% and
91%, respectively (Table 4). We found no significant influence
of sex on the SF levels of sGAG or aggrecan (data not shown).
However, age correlated negatively with sGAG concentration
in the AA group (rS = -0.292) and aggrecan concentration in
the AI and CI groups (rS = -0.335 and rS = -0.230 respec-
tively).
ARGS and aggrecan fragment release in relation to time 
after injury
After knee injury involving either a MEN alone (Figures 4a,b),
or an ACL injury with or without associated MEN (Figures
4c,d), the SF levels of both sGAG and ARGS fragments were
elevated within the first four weeks compared with REF (P <
0.001). Notably, the median elevations for MEN and ACL
patients were more than 200-fold compared with REF for
ARGS, but only two- to three-fold for sGAG. For time spans
more than four weeks after injury, the sGAG levels of the MEN
and ACL groups were not different from the REF group,
whereas the ARGS levels continued to differ from REF (except
for 26 to 52 weeks after meniscal injury). At none of the time
intervals were there any differences between MEN and ACL
groups for ARGS or sGAG in SF.
Proportion of aggrecan detected as ARGS neoepitope in 
study groups
The proportions of aggrecan fragments in SF detected as
ARGS neoepitope fragments out of all SF proteoglycan
(measured by Alcian blue precipitation) were increased in all
study groups compared with REF (P < 0.001; Figure 5). The
proportion in the AA group was the highest, 111-fold elevated
compared with REF, and in the CI group the least increased,
two-fold compared with the REF group. The median propor-
tion of ARGS in REF was 1% and ranged in the diagnostic
groups from 2% (CI) to 110% (AA). The proportion of ARGS
Figure 2
Regression analysis of aggrecan fragment data Regression analysis of aggrecan fragment data. The same samples of 
synovial fluid were analyzed by three different assays (see Material and 
Methods for details). Concentration of aggrecan fragments carrying the 
neoepitope ARGS by ELISA versus (a) sGAG concentration by Alcian 
blue precipitation (n = 293) and versus (b) aggrecan concentration by 
1-F21 ELISA (n = 285). Solid lines show the first-order regression. 
Note the logarithmic X- and Y-axes. Spearman's rank order correlations 
(rS) are given for each relationship with P < 0.0001.
Table 3
Synovial fluid aggrecan fragment data in all subjects
OA-1 ARGS ELISA
(pmol ARGS/ml)
Alcian blue precipitation
(μg sGAG/ml)
1-F21 ELISA
(μg aggrecan/ml)
n 295 293 285
Mean 75 104 199
Median 10 74 120
Range 0.5 to 961 5 to 728 0.2 to 1912Available online http://arthritis-research.com/content/11/3/R92
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of all aggrecan as a marker for joint disease had a sensitivity of
65% and a specificity of 96% (Table 4).
Discussion
Aggrecanase cleavage at the Glu-Ala bond in the IGD is
important both in animal [6,7,10,11,13,14] and human
[4,9,15,17] joint disease. However, previous analyses of larger
series of human samples of serum or SF used assays that
were not specific for aggrecan fragments carrying this specific
neoepitope [1,3,24,26,29-32]. This limits our ability to inter-
pret the results in terms of activity of specific proteases. The
work presented here confirms that aggrecanase cleavage in
the IGD is a major contributor to aggrecan degradation in
human joint pathology, and extends our understanding of the
relative contribution of aggrecanase activity in different human
joint diseases. We found greatly increased SF concentrations
of aggrecan ARGS fragments in several different joint dis-
eases compared with the healthy knee reference group, differ-
ences that were only to a small extent reflected by enhanced
concentrations of aggrecan fragments in general or sulfated
glycosaminoglycans. We also found that the elevation in SF
ARGS concentration was most dramatic early after a knee
injury, and then decreased to lower levels 12 weeks after the
injury, albeit still significantly different from the healthy knee
reference group. This suggests that the enhanced aggrecan
cleavage in the IGD by aggrecanase caused by the acute joint
insult remains increased for several years. Similar long-term
changes after knee injury in SF levels of stromelysin (MMP-3)
have been reported [2,28].
Study design and methodology
The range of ARGS concentrations within each study group
was substantial, with the exception of the healthy knee refer-
ence group. In part, this can be explained by the cross-sec-
tional study design, with the grouping together of individuals
with varying severity of injury and disease activity. However, it
is also known that the variability of SF markers is greater than
for serum and urine markers [32]. Despite the considerable
range observed, we note that all study groups differed signifi-
cantly from the reference group regarding ARGS concentra-
tions. Based on previous studies it is most likely that the knee
injury groups are not homogenous regarding progression of
OA, but are comprised of progressors and non-progressors
[33,34]. It is plausible that heterogeneities like these also influ-
ence the ARGS concentrations, and could partly explain the
variations seen in these groups.
The lower limit of linearity of the ARGS ELISA in SF was 1
pmol/ml SF, and samples below this level were assigned half
that value to allow statistical analysis. All study groups had sig-
nificantly lower proportions of samples below the lower limit of
detection compared with the knee healthy reference group.
As a validation of the ARGS ELISA, we analyzed a subset of
SF samples, purified by dissociative cesium chloride density
Figure 3
Aggrecan fragment concentrations in the study groups Aggrecan fragment concentrations in the study groups. Concentrations 
of (a) ARGS fragments, (b) sulfated glycosaminoglycan (sGAG), and 
(c) aggrecan in the study groups healthy knee reference (REF), acute 
inflammatory arthritis (AA), acute knee injury (AI), chronic knee injury 
(CI), and knee osteoarthritis (OA). The boxes define the 25th and 75th 
percentiles with a line at the median, error bars defining the 10th and 
90th percentiles and circles represents individual outliers. Note that in 
panel (a) the median level of the chronic injury group is the same as the 
lower limit of the box; 0.5 pmol ARGS/ml. After Bonferroni correction, P 
values below 0.013 are considered significant to retain the 0.05 overall 
significance level.Arthritis Research & Therapy    Vol 11 No 3    Larsson et al.
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gradient centrifugation, with quantitative western blots using
the same ARGS antibody and standard as in the ELISA. The
results verified that samples below the detection level of the
ARGS ELISA had very low levels of ARGS.
The similarity in the Western blot analysis of loaded and cap-
tured aggrecan ARGS fragments show that the ARGS frag-
ments present in the standard and the cesium chloride D1
preparation of an SF sample are captured by the anti-KS plate.
The weaker immuno-reaction seen for SF ARGS fragments
captured by the ELISA plate, compared with fragments cap-
tured from the standard, is most likely a reflection of a lower
total ARGS concentration in these SFs compared with the
standards.
The strategy applied in the ARGS ELISA of capturing frag-
ments with the anti-KS antibody limits detection of ARGS frag-
ments to those also containing part of the KS domain.
Although there are known cleavage sites for proteases such
as MMPs, cathepsins, and calpains between 393ARGS and
Table 4
Sensitivity and specificity of aggrecan fragment measurements
Assay Cut-off AUC Sensitivity Specificity
OA-1 ARGS ELISA 1 pmol ARGS/ml 82% 67% 92%
Alcian blue precipitation 88.5 μg sGAG/ml 63% 40% 92%
1-F21 ELISA 188.5 μg aggrecan/ml 53% 32% 91%
ARGS/sGAG* 5% 83% 65% 96%
*The molar proportion of aggrecan fragments in SF detected as ARGS neoepitope fragments, measured by Alcian blue precipitation and the 
ARGS ELISA respectively.
Sensitivity = the proportion of positives (diseased) correctly identified by the test.
Specificity = the proportion of negatives (healthy) correctly identified by the test.
AUC = area under receiver operating characteristic (ROC) curve.
Cut-offs were chosen based on ROC curve analysis where the sum of sensitivity and specificity was highest.
Figure 4
Aggrecan release after knee injury Aggrecan release after knee injury. Samples were ordered by time after knee injury (weeks) and by (a, b) meniscal injury alone (MEN) or (c, d) by 
anterior cruciate ligament rupture with or without an associated meniscus injury (ACL). Values are median concentrations of sulfated gly-
cosaminoglycan (sGAG; open squares) and ARGS (filled squares) with 25th and 75th percentiles, compared with the medians (dashed lines) and 
25th and 75th percentiles (shaded area) of the reference group on logarithmic Y-axes. Significant difference against the reference group at the 0.001 
(***), 0.01 (**) and 0.05 (*) levels after Bonferroni correction is indicated.Available online http://arthritis-research.com/content/11/3/R92
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the KS domain stretching from amino acid 676 to 848, these
cleavage sites were all confirmed to occur by in vitro experi-
ments [5]; Sandy and Verscharen showed in SF the presence
of a 100 kDa ARGS band ('Species f') estimated to stretch to
amino acids 800 to 900 [17]. We detected small amounts of
a similar band in SF purified by chromatography or by associ-
ative A1 fractioning which, when deglycosylated, migrated to
50 to 70 kDa; the intensity of the band corresponded to about
3% of the total ARGS signal (data not shown). By use of a cal-
culation model [35], we estimate these 393ARGS fragments to
stretch to amino acids 690 to 750 (data not shown). With the
KS domain starting at amino acid 676, these fragments con-
tain part of the domain necessary for capture. We can not,
however, completely rule out the presence of SF ARGS frag-
ments not containing the KS necessary for detection.
The inter assay CV for the ARGS ELISA was to a large part
caused by the use of two different lot numbers of the KS cap-
ture plates supplied by Biosource. The samples were, how-
ever, analysed blinded with diagnostic groups spread evenly,
so the change of lot numbers had no effect on the observed
group differences in ARGS concentrations.
Aggrecan and ARGS fragments as biomarkers in SF
As reported [1,2,24], the group differences in aggrecan con-
tent determined by Alcian blue precipitation or by ELISA with
the 1-F21 antibody were small with a maximum of a two-fold
increase compared with the REF. Only AA and AI were shown
to have significantly elevated levels of sGAG and aggrecan
compared with REF.
In contrast to the Alcian blue precipitation method and the 1-
F21 ELISA, the ARGS ELISA is highly specific regarding
neoepitope and presence of KS on the fragments. Even so, the
ARGS neoepitope concentrations correlated with both sGAG
and 1-F21 aggrecan concentrations in SF, consistent with
previous findings showing that a significant portion of the
sGAG and aggrecan content in human SF consisted of
neoepitope fragments such as the ARGS fragments meas-
ured here, or MMP-generated 361FFGV fragments [18,36].
The differences in group median values of ARGS were, how-
ever, much greater than for either sGAG or 1-F21 aggrecan.
All disease groups were significantly different from the REF,
with as much as 177-fold increased levels of ARGS in the AA
group. With specificities of 91 to 92%, the concentration of
ARGS neoepitope fragments had a sensitivity of 67% in differ-
entiating diseased from healthy patients, compared with
sGAG or 1-F21 aggrecan, which had lower sensitivities of
40% and 32%, respectively. Quantification in SF of ARGS
fragments generated by aggrecanases by a neoepitope-spe-
cific ELISA is clearly a more powerful tool to distinguish dis-
eased and injured joints from healthy than quantification of
aggrecan fragments either by 1-F21 ELISA or by measuring
sGAG concentrations.
Proportion of aggrecan detected as ARGS neoepitope
Acknowledging that there are uncertainties in our assumptions
of molecular weight and degree of glycosylation of the average
aggrecan fragment in SF, and of the molecular weight of the
standard, uncertainties that make ARGS proportions of aggre-
can greater than 100% possible, the diagnostic groups never-
theless showed large differences in the proportion of SF
aggrecan fragments generated by aggrecanase IGD activity.
In the two groups most strongly associated with high joint dis-
ease activity, acute inflammatory arthritis and acute knee injury,
a majority of the aggrecan fragments were indeed shown to be
the result of aggrecanase IGD activity, whereas the other
groups had much lower proportions. These results corrobo-
rate those previously obtained by western blots [4].
Interpretation of elevated SF levels of ARGS
Based solely on data available in this paper, the elevated SF
levels of ARGS in disease, particularly in the acute inflamma-
tory arthritis and acute injury samples, could be explained by
Figure 5
Proportion ARGS of aggrecan in the study groups Proportion ARGS of aggrecan in the study groups. The molar propor-
tion of aggrecan fragments in synovial fluid (SF; measured by Alcian 
blue precipitation) detected as ARGS neoepitope fragments (meas-
ured by ARGS ELISA) in the study groups healthy knee reference 
(REF), acute inflammatory arthritis (AA), acute knee injury (AI), chronic 
knee injury (CI), and knee osteoarthritis (OA). The boxes define the 25th 
and 75th percentiles with a line at the median, error bars defining the 
10th and 90th percentiles and circles represents individual outliers. After 
Bonferroni correction, P values below 0.013 are considered significant 
to retain the 0.05 overall significance level. Conversion from microgram 
sulfated glycosaminoglycan (sGAG)/ml to pmol aggrecan/ml was 
made assuming an average aggrecan molecular weight of 1.5 × 106 g/
mol and that 75% of this weight was sGAG.Arthritis Research & Therapy    Vol 11 No 3    Larsson et al.
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enhanced aggrecanase activity against aggrecan resident in
the joint cartilage matrix, or against newly synthesized and
secreted aggrecan [37]. ADAMTS-5 (aggrecanase-2) was
shown to co-localize with hyaluronan surrounding chondro-
cytes in both normal and osteoarthritic cartilage [38]. How-
ever, if enhanced synthesis of aggrecan in combination with
aggrecanase activity were to explain the enhanced SF levels
of ARGS, an equal increase in the SF levels of G3 was to be
expected. This is not the case; we have in quantitative western
blot analysis of 30 of these samples seen no significant differ-
ence in SF levels of G3 of any of the diagnostic groups com-
pared with healthy knee references [4]. We therefore suggest
that an increased aggrecanase activity against the IGD
domain of resident aggrecan best explains the enhanced SF
levels of ARGS seen in these diagnostic groups.
The source of the aggrecan fragments
SF is more proximate to the location of joint cartilage and
aggrecan degradation than serum or urine, and may therefore
better reflect local pathologic processes in the joint being
studied. The observed group differences are thus likely to
reflect differences in local knee joint pathology. The fragments
observed in SF originate in a major part from the joint cartilage,
while minor proportions may be released from menisci and lig-
aments [39,40].
Conclusions
Our findings confirm that aggrecanase cleavage at the 392Glu-
393Ala bond in the IGD of aggrecan is enhanced in joint pathol-
ogy, most markedly in acute inflammatory arthritis and early
after knee injury, but also in knee OA. The enhanced aggreca-
nase IGD cleavage is detectable by ELISA as ARGS frag-
ments in the SF. We show that measuring SF concentrations
of ARGS is more sensitive in distinguishing diseased and
injured joints from healthy ones than methods that do not rely
on the specific detection of this aggrecan neoepitope. The
ARGS ELISA could be used to monitor aggrecanase activity
in joint disease, and to monitor the efficacy of interventions to
inhibit this protease activity in joint disease or model systems.
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